DLBCL patients treated with CD19 CAR T cells experience a high burden of organ toxicities but low nonrelapse mortality.
Blood Adv
; 4(13): 3024-3033, 2020 07 14.
Article
in En
| MEDLINE
| ID: mdl-32614964
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Receptors, Antigen, T-Cell
/
Lymphoma, Large B-Cell, Diffuse
Limits:
Humans
Language:
En
Journal:
Blood Adv
Year:
2020
Document type:
Article
Country of publication:
United States